Imugene Logo

About Imugene

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 for gastric cancer; VAXINIA is in phase 1 MAST trial for patients with metastatic or advanced solid tumours; and CHECKvacc oncolytic virotherapy is in phase 1 clinical trial against metastatic triple negative breast cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform; and a license agreement with Precision Biosciences Inc. to acquire azer-cell allogeneic CD19 CAR Tcell therapy program. Imugene Limited is based in Sydney, Australia.